Clinical Trial Update: Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 pilot trial evaluating Rituximab for the treatment of acute immune thrombocytopenic purpura (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Status: COMPLETED